AFINITOR
As listed in the register: AFINITOR
10 mg · tablet
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Everolimus
- Made by
- Novartis Pharmaceuticals Canada Inc
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (Everolimus). It describes the substance, not this exact product.
Everolimus is an inhibitor of mammalian target of rapamycin (mTOR), a serine-threonine kinase, downstream of the PI3K/AKT pathway.
The mTOR pathway is dysregulated in several human cancers and in tuberous sclerosis complex (TSC).
Following the administration of a 3 mg single dose of radiolabeled everolimus in patients who were receiving cyclosporine, 80% of the radioactivity was recovered from the feces, while 5% was excreted in the urine.
Effect of Food: In healthy subjects, a high-fat meal (containing approximately 1000 calories and 55 grams of fat) reduced systemic exposure to Everolimus 10 mg (as measured by AUC) by 22% and the peak blood concentration C max by 54%.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-08-14
Safety of the active substance
From the US prescribing label for the same active substance (Everolimus). It describes the substance, not this exact product.
- Everolimus is contraindicated in patients with clinically significant hypersensitivity to everolimus or to other rapamycin derivatives [see Warnings and Precautions ( 5.3 )].
- Clinically significant hypersensitivity to everolimus or to other rapamycin derivatives.
Most common adverse reactions (incidence ≥30%) include stomatitis, infections, rash, fatigue, diarrhea, edema, abdominal pain, nausea, fever, asthenia, cough, headache, and decreased appetite.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United States10 matching products
European UnionNo exact match for this strength and form
Spain14 matching products
Netherlands20 matching products
- Everolimus Synthon 10 mg 10 mg · tablet4 makers
- Everolimus Sandoz 10 mg 10 mg · tablet2 makers
- Afinitor 10 mg 10 mg · tablet
- Everofin 10 mg 10 mg · tablet
- Everolimus Accord 10 mg 10 mg · tablet
- Everolimus Biocon 10 mg tabletten 10 mg · tablet
- Everolimus CF 10 mg 10 mg · tablet
- Everolimus Ethypharm 10 mg tabletten 10 mg · tablet
Details
| Made by | Novartis Pharmaceuticals Canada Inc |
|---|---|
| Active substance | Everolimus |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 10 mg |
| Form | tablet |
| Classification | L04AH02 · Cancer treatments and immune-system medicines |
| Route | oral |
| Dispensing (as stated by the register) | PRESCRIPTION |
| Status | Marketed |
| Marketed | Yes, according to the register |
| DIN | 02339528 |
| DPD drug code | 82512 |
Source: Drug Product Database · 2026-09-30 · not reviewed by a clinician
Contains information licensed under the Open Government Licence – Canada. Reuse terms: Open Government Licence – Canada.
Other strengths and forms
3 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.